Dacryocystitis Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Market is Segmented by Indication (Acute, Chronic, and Other Indications), Distribution Channel (Institutional Sales and Retail Sales), and Geography.

Dacryocystitis Market Size

DCT
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 4.20 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Dacryocystitis Market

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Dacryocystitis Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Dacryocystitis Market Analysis

The dacryocystitis market studied is anticipated to register a CAGR of nearly 4.2%, during the forecast period.

Certain factors that are driving the market growth include a rise in the prevalence of eye infections and increasing clinical research and subsequent new product launches.

Dacryoadenitis is an inflammation of the lacrimal gland. Infections are rare and may be acute or chronic. Patients with acute dacryoadenitis suffer from a tender area of erythema and swelling in the lateral part of the upper lid. It may lead to preseptal or orbital cellulitis or may suppurate into an abscess.

As per the study titled 'Fungal infections of the eye', fungal dacryocystitis accounts for approximately 5% of all acquired dacryocystitis and around 14% of cases of congenital dacryocystitis. Women are affected more frequently with all forms of dacryocystitis than men, probably because of anatomically narrower nasolacrimal ducts. It mostly affects individuals in their 50s or 60s.

Dacryocystitis Market Trends

This section covers the major market trends shaping the Dacryocystitis Market according to our research experts:

Acute Dacryocystitis Holds Significant Share in the Dacryocystitis Market

Dacryocystitis can be acute or chronic and congenital or acquired. Symptoms of acute dacryocystitis start suddenly and often include fever and pus from the eye. Bacterial infections are usually the cause of acute dacryocystitis, and antibiotic treatment usually resolves the infection within a few days. People with acute dacryocystitis often experience more severe symptoms than those with chronic dacryocystitis. However, in all age groups, acute dacryocystitis generally resolves quickly after taking oral antibiotics.

seg 2 dct.png

North America Dominates the Dacryocystitis Market

The United States has witnessed a considerable rise in the number of dacryocystitis patients. According to the 2019 study (Grant D Gilliland et al), in adults, females are afflicted more commonly by dacryocystitis. Most studies demonstrate that 70-83% of cases of dacryocystitis occur in females. Congenital dacryocystitis occurs with equal frequency in both sexes. Moreover, the ease in the US government's regulations and the availability of funds from various organizations, like the National Institute of Health, have provided the potential for researchers to invest more in drug discovery for the disease.

geo dct.PNG

Dacryocystitis Industry Overview

The dacryocystitis market is competitive and consists of a few major players. Companies like Aurobindo Pharma, Bess Medizintechnik GmbH, FCI Ophthalmics, Glaxosmithkline PLC, Kaneka Corporation, Mylan NV, Nosch, Orex Pharma Pvt Ltd, and Pfizer Inc., hold the substantial share in the market.

Dacryocystitis Market Leaders

  1. Pfizer Inc.

  2. Aurobindo Pharma

  3. Orex Pharma Pvt Ltd

  4. Nosch

  5. Mylan NV

*Disclaimer: Major Players sorted in no particular order

comp dct.png
Need More Details on Market Players and Competitors?
Download PDF

Dacryocystitis Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rise in Prevalence of Eye Infections

      2. 4.2.2 Increasing Clinical Research and Subsequent New Product Launches

    3. 4.3 Market Restraints

      1. 4.3.1 Less Patient Awareness Regarding Various Treatment Procedures

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Indication

      1. 5.1.1 Acute

      2. 5.1.2 Chronic

      3. 5.1.3 Other Indications

    2. 5.2 By Distribution Channel

      1. 5.2.1 Institutional Sales

      2. 5.2.2 Retail Sales

    3. 5.3 By Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Aurobindo Pharma

      2. 6.1.2 Bess Medizintechnik GmbH

      3. 6.1.3 FCI Ophthalmics

      4. 6.1.4 Glaxosmithkline PLC

      5. 6.1.5 Kaneka Corporation

      6. 6.1.6 Mylan NV

      7. 6.1.7 Nosch

      8. 6.1.8 Orex Pharma Pvt Ltd

      9. 6.1.9 Pfizer Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Dacryocystitis Industry Segmentation

As per the scope of the report, dacryocystitis refers to an infection of the tear sac (lacrimal sac) in the inner corner of the eye. It causes pain, redness, and swelling over the inner aspect of the lower eyelid and epiphora.

By Indication
Acute
Chronic
Other Indications
By Distribution Channel
Institutional Sales
Retail Sales
By Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Dacryocystitis Market Research FAQs

The Dacryocystitis Market is projected to register a CAGR of 4.20% during the forecast period (2024-2029)

Pfizer Inc. , Aurobindo Pharma , Orex Pharma Pvt Ltd, Nosch and Mylan NV are the major companies operating in the Dacryocystitis Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Dacryocystitis Market.

The report covers the Dacryocystitis Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Dacryocystitis Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Dacryocystitis Industry Report

Statistics for the 2024 Dacryocystitis market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Dacryocystitis analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Dacryocystitis Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)